AlphaFold predicted structure
AMACR · Q9UHK6

Mean pLDDT
95.8/ 100
Very high
382 residues
Confidence breakdown
- Very high(≥ 90)95%
- Confident(70–90)4%
- Low(50–70)1%
- Very low(< 50)1%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
alpha-methylacyl-CoA racemase
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Cholestasis
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalHereditary neuropathy or pain disorder
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalPeroxisomal disorders
BIALLELIC, autosomal or pseudoautosomalRetinal disorders
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomal+2 more panels — install the extension to see the full list inline on any page.
alpha-methylacyl-CoA racemase deficiency
Congenital bile acid synthesis defect type 4
congenital bile acid synthesis defect 4
hereditary disease
retinitis pigmentosa
hair color
IgA glomerulonephritis
mitochondrial complex I deficiency
spastic ataxia
prostate carcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Alpha-methylacyl-CoA racemase
Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters (PubMed:10655068, PubMed:11060359, PubMed:7649182). Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither 3-methyl-branched nor linear-chain acyl-CoAs (PubMed:10655068, PubMed:11060359, PubMed:7649182)
AMACR · Q9UHK6

Mean pLDDT
95.8/ 100
Very high
382 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0